As­traZeneca's for­mer an­tibi­otics unit claims a PhI­II win in drug-re­sis­tant bac­te­ria af­fect­ing sick­ly pa­tients

The man­age­ment team at En­ta­sis, As­traZeneca’s old an­tibi­otics unit spun out six years ago, has a new dataset it’s sim­ply de­light­ed to share.

En­ta­sis re­vealed Phase III da­ta out­lin­ing how an an­tibi­ot­ic for in­fec­tions caused by Acine­to­bac­ter bau­man­nii reached its pri­ma­ry end­point of non-in­fe­ri­or­i­ty. Re­searchers com­pared the pro­gram — known as sul­bac­tam-dur­lobac­tam or SUL-DUR — to the an­tibi­ot­ic col­istin, say­ing their drug saw low­er lev­els of all-cause mor­tal­i­ty af­ter four weeks in treat­ment-re­sis­tant pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER